Brawn Biotech

{
  "main_header": {
    "sid": 479596,
    "name": "Brawn Biotech",
    "stock_name": "Brawn Biotech",
    "full_name": "Brawn Biotech Ltd",
    "name_url": "stocks-analysis/brawn-biotech",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "21.99",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "21.99",
    "mcapval": "7.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530207,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE899B01015",
    "curr_date": "Aug 04, 03:30 PM",
    "curr_time": "03:19 AM",
    "last_traded_at": "Aug 04, 03:30 PM IST",
    "bse_nse_vol": "1 ",
    "exc_status": "Active",
    "traded_date": "Aug 04, 2026",
    "traded_date_str": "2026 08 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/brawn-biotech-479596-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4111727",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BrawnBiotechLtd_mojoScore_4111727.png",
        "date": "2026-07-21 08:06:09",
        "description": "Brawn Biotech Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Jul 2026, driven primarily by a shift in technical indicators signalling a mildly bullish trend. Despite this upgrade, the company continues to face significant challenges in valuation and financial performance, reflecting a complex investment profile for market participants."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-4099956",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BrawnBiotechLtd_mojoScore_4099956.png",
        "date": "2026-07-14 08:03:52",
        "description": "Brawn Biotech Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 Jul 2026, reflecting deteriorating technical indicators, flat financial performance, and weakening long-term fundamentals. The company’s micro-cap status, combined with negative operating metrics and bearish market signals, has prompted a reassessment of its investment appeal."
      },
      {
        "title": "Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4091384",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BrawnBiotechLtd_mojoScore_4091384.png",
        "date": "2026-07-07 08:04:34",
        "description": "Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 6 July 2026. This change is primarily driven by a shift in technical indicators, despite the company’s ongoing fundamental challenges and flat financial performance in the latest quarter."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Financials and Technical Setbacks",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-weak-financials-and-technical-setbacks-4083862",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BrawnBiotechLtd_mojoScore_4083862.png",
        "date": "2026-07-02 08:05:28",
        "description": "Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 1 July 2026. This decisive change reflects deteriorating technical indicators, weak financial trends, poor valuation metrics, and declining quality scores, signalling heightened risk for investors amid flat quarterly results and ongoing operating losses."
      },
      {
        "title": "Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4068088",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BrawnBiotechLtd_mojoScore_4068088.png",
        "date": "2026-06-23 08:04:46",
        "description": "Brawn Biotech Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 22 June 2026, driven primarily by a marked improvement in technical indicators. However, the company’s fundamental and valuation metrics remain weak, reflecting ongoing operational challenges and a precarious financial position. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Financials and Technical Setbacks",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-weak-financials-and-technical-setbacks-4058145",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BrawnBiotechLtd_mojoScore_4058145.png",
        "date": "2026-06-17 08:03:29",
        "description": "Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 June 2026, reflecting deteriorating technical indicators and persistent financial weaknesses. The micro-cap pharmaceutical company’s Mojo Score has declined to 23.0, signalling heightened risk for investors amid sideways technical trends and flat quarterly performance."
      },
      {
        "title": "Are Brawn Biotech Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-brawn-biotech-ltd-latest-results-good-or-bad-4021761",
        "imagepath": "",
        "date": "2026-05-29 19:36:43",
        "description": "Brawn Biotech Ltd's latest financial results reflect a challenging operational environment. In Q2 FY26, the company reported a net loss of ₹0.04 crores, a significant shift from a profit of ₹0.23 crores in the previous quarter. This change was largely attributed to a lack of other income, which had previously contributed positively to profitability. Revenue remained flat at ₹0.12 crores, indicating stagnation in sales performance.\n\nThe operating margin, excluding other income, fell sharply to -33.33%, contrasting with a positive margin of 25.0% in Q1 FY26. This substantial decline highlights significant operational inefficiencies and cost pressures that the company has been unable to manage effectively. Additionally, the return on equity for the latest fiscal year stood at -16.49%, indicating a failure to generate positive returns for shareholders.\n\nOver the past five years, Brawn Biotech has experienced a ..."
      },
      {
        "title": "When is the next results date for Brawn Biotech Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-brawn-biotech-ltd-4007250",
        "imagepath": "",
        "date": "2026-05-22 23:18:06",
        "description": "The next results date for Brawn Biotech Ltd is scheduled for 29 May 2026...."
      }
    ],
    "total": 427,
    "sid": "479596",
    "stock_news_url": "https://www.marketsmojo.com/news/brawn-biotech-479596"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Jul-2026",
      "details": "Certificate under Reg 74(5)",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Jun-2026",
      "details": "Closure of Trading Window for the quarter ended June 30 2026.",
      "source": "BSE"
    },
    {
      "caption": "Intimation Regarding Non-Applicability Of Regulation 23(9)",
      "datetime": "30-May-2026",
      "details": "Intimation regarding non-applicability of Regulation 23(9)",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Brawn Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 12 Sep 18",
          "dt": "2018-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-07-21 08:06:09

Brawn Biotech Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Jul 2026, driven primarily by a shift in technical indicators signalling a mildly bullish trend. Despite this upgrade, the company continues to face significant challenges in valuation and financial performance, reflecting a complex investment profile for market participants.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-07-14 08:03:52

Brawn Biotech Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 Jul 2026, reflecting deteriorating technical indicators, flat financial performance, and weakening long-term fundamentals. The company’s micro-cap status, combined with negative operating metrics and bearish market signals, has prompted a reassessment of its investment appeal.

Read full news article

Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-07-07 08:04:34

Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 6 July 2026. This change is primarily driven by a shift in technical indicators, despite the company’s ongoing fundamental challenges and flat financial performance in the latest quarter.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Financials and Technical Setbacks

2026-07-02 08:05:28

Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 1 July 2026. This decisive change reflects deteriorating technical indicators, weak financial trends, poor valuation metrics, and declining quality scores, signalling heightened risk for investors amid flat quarterly results and ongoing operating losses.

Read full news article

Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-06-23 08:04:46

Brawn Biotech Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 22 June 2026, driven primarily by a marked improvement in technical indicators. However, the company’s fundamental and valuation metrics remain weak, reflecting ongoing operational challenges and a precarious financial position. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Financials and Technical Setbacks

2026-06-17 08:03:29

Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 June 2026, reflecting deteriorating technical indicators and persistent financial weaknesses. The micro-cap pharmaceutical company’s Mojo Score has declined to 23.0, signalling heightened risk for investors amid sideways technical trends and flat quarterly performance.

Read full news article

Are Brawn Biotech Ltd latest results good or bad?

2026-05-29 19:36:43

Brawn Biotech Ltd's latest financial results reflect a challenging operational environment. In Q2 FY26, the company reported a net loss of ₹0.04 crores, a significant shift from a profit of ₹0.23 crores in the previous quarter. This change was largely attributed to a lack of other income, which had previously contributed positively to profitability. Revenue remained flat at ₹0.12 crores, indicating stagnation in sales performance. The operating margin, excluding other income, fell sharply to -33.33%, contrasting with a positive margin of 25.0% in Q1 FY26. This substantial decline highlights significant operational inefficiencies and cost pressures that the company has been unable to manage effectively. Additionally, the return on equity for the latest fiscal year stood at -16.49%, indicating a failure to generate positive returns for shareholders. Over the past five years, Brawn Biotech has experienced a ...

Read full news article

When is the next results date for Brawn Biotech Ltd?

2026-05-22 23:18:06

The next results date for Brawn Biotech Ltd is scheduled for 29 May 2026....

Read full news article

View All News